Changes of Serum VEGF and b-FGF in 26 Patients with Breast Cancer after Treatment with Hang-Am-Dan (HAD), an Antiangiogenic Botanical Prescription

  • Yoo Hwa Seung (East-West Cancer Center, Dunsan Oriental Hospital of Daejon University) ;
  • Lee Nam Heon (East-West Cancer Center, Dunsan Oriental Hospital of Daejon University) ;
  • Cho Jung Hyo (East-West Cancer Center, Dunsan Oriental Hospital of Daejon University) ;
  • Lee Yeon Weol (East-West Cancer Center, Dunsan Oriental Hospital of Daejon University) ;
  • Son Chang Gue (East-West Cancer Center, Dunsan Oriental Hospital of Daejon University) ;
  • Kang Wee Chang (Department of Information and Statistics, Daejeon University) ;
  • Cho Chong Kwan (East-West Cancer Center, Dunsan Oriental Hospital of Daejon University)
  • Published : 2005.12.01

Abstract

Objectives: Recently, angiogenesis has gained an increasing interest as a prognostic factor in breast cancer. In this study we aimed to assess the anti angiogenic effects of HAD, a botanical anticancer remedy which has been prescribed in Daejeon University Oriental Hospital in Korea, on patients with breast carcinoma by measuring the serum vascular endothelial growth factor (VEGF), basic fibroblast growth factor (b-FGF) and platelets levels. Methods: The study included 26 consecutive breast cancer patients (mean age$\pm$standard deviation: 47.5$\pm$8.7 years) with stage II to IV disease who were treated with HAD (mean duration $\pm$ standard deviation: 264.5$\pm$121.6 days). In addition to routine laboratory and staging procedures, serum VEGF, b-FGF levels and platelet counts were determined as antiangiogenic markers. The antiangiogenic effects of HAD were evaluated by analyzing the differences between the values of the antiangiogenic markers before and after the treatment with HAD. Results: Serum b-FGF concentrations were significantly reduced after the treatment with HAD (P=0.042). Serum VEGF concentrations were found to have a somewhat decreasing change, though the change was not statistically significant (P=0.229). Platelet counts had little changes (P=O.80). Conclusions: It is supposed that HAD has effects on decreasing the serum b-FGF levels related with the clinical outcome of breast cancer patients.

Keywords